Logo

Caroline Loew, Stanley Lapidus, Robert Langer

Dec 07, 2018

Glympse Bio has appointed Caroline Loew as the firm's president and CEO. Loew previously served as VP, heading of R&D strategy and planning at Bristol-Myers Squibb. In addition, she has served in senior roles at Merck and phRMA over the past 20 years, where she led teams in drug development, regulatory policy, market access, and commercial. 

Glympse has also appointed Stanley Lapidus as the firm's chairman and Robert Langer to the firm's board of directors. Lapidus has been the founding CEO of four medical technology companies, including Cytyc, Exact Sciences, Helicos, and SynapDx.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.